Gemfibrozil-d6

• Description :

  Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

• Product Name Alternative :

  CI-719-d6

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Cytochrome P450; PPAR

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Metabolic Disease; Cardiovascular Disease

• Purity :

  98.00

• Solubility :

  10 mM in DMSO

• Smiles :

  OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])CCCOC1=C(C=CC(C)=C1)C)=O

• Molecular Formula :

  C15H16D6O3

• Molecular Weight :

  256.37

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277 (48) :45984-91. Epub 2002 Sep 18.|[3]Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232 (2) :309-17.|[4]Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30 (12) :1352-6.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1184986-45-5]